Innovative drug to treat obesity and overweight arrives in Brazil
One of the main benefits of Belviq® is its safety, as it is not a stimulant nor a narcotic. Another benefit is that the patient continues to lose weight over time.
Clinical studies have shown that after 52 weeks of treatment, almost half of lorcaserin patients lose 5% or more of their body weight, and 22% of those patients lose 10% or more of their body weight¹.
Available throughout Brazil, the product works best for weight loss and maintenance when complementing a lifestyle change – a good diet and physical activity. Being neither a narcotic nor a stimulant, Belviq® has good tolerability and therefore promotes adherence to treatment. Cardiovascular safety has also been proven by clinical studies – the rate of cardiovascular events with drug use was similar to the placebo group²,1.
"Belviq® further expands our solutions for combating obesity and overweight, and provides safety and convenience to doctors and their patients. The combination of effectiveness, safety and tolerability of this innovative drug helps reduce the yo-yo effect, which affects many patients suffering from this disease," said Roberta Junqueira, Commercial Director at Eurofarma.
For more information, visit https://www.eurofarma.com.br/